Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Sarcoma 1Dermatologic 1

Conditions

Sarcoma 3Sarcoma, Synovial 2Rhabdomyosarcoma 1Rhabdoid Tumor 1Retinoblastoma 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasms, Germ Cell and Embryonal 1Melanoma 1Medulloblastoma 1Liposarcoma, Myxoid 1Hepatoblastoma 1Fallopian Tube Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Brain Neoplasms 1Bone Neoplasms 1Advanced Fallopian Tube Carcinoma 1

Interventions

Paclitaxel 3aflibercept 2Taxes 2Specimen Handling 2Psychiatric Rehabilitation 2Magnetic Resonance Spectroscopy 2Gene Expression Profiling 2Fentanyl 2Cisplatin 2Carboplatin 2tinostamustine 1sodium thiosulfate 1rucaparib 1pelcitoclax 1motexafin lutetium 1entinostat 1cobimetinib 1X-Rays 1Topotecan 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Serotonin Plasma Membrane Transport Proteins 1Ropivacaine 1Radiotherapy 1Radiation 1Quality of Life 1Polymerase Chain Reaction 1Platinum 1Patient Reported Outcome Measures 1Oxaliplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × Leukapheresis × Sarcoma × Clear all
NCT02650986 2025-06-17

Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

Roswell Park Cancer Institute

Phase 1/2 Active not recruiting
15 enrolled 12 charts
DermatologicGynecologicSarcoma

Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Synovial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡